PubRank

Daniel E Speiser

Author PubWeight™ 83.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest 2011 3.28
2 Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 2007 2.59
3 Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012 1.77
4 New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006 1.74
5 BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2009 1.71
6 Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 2002 1.68
7 Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002 1.58
8 T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 2013 1.57
9 Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002 1.48
10 RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2007 1.47
11 Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002 1.44
12 Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2013 1.42
13 The three main stumbling blocks for anticancer T cells. Trends Immunol 2012 1.38
14 Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010 1.33
15 Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods 2005 1.33
16 Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004 1.29
17 Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009 1.25
18 Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods 2006 1.13
19 Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 2006 1.11
20 Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 2009 1.09
21 Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2003 1.09
22 Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012 1.06
23 The human T cell response to melanoma antigens. Adv Immunol 2006 1.05
24 Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol 2009 1.01
25 Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol 2012 1.01
26 Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2010 1.01
27 The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011 1.00
28 Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003 1.00
29 SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013 1.00
30 Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003 1.00
31 Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 2011 0.99
32 Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC. Proc Natl Acad Sci U S A 2003 0.99
33 Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005 0.99
34 Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. J Immunol 2009 0.98
35 In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J Immunol 2007 0.97
36 Assessing ageing of individual T lymphocytes: mission impossible? Mech Ageing Dev 2007 0.95
37 Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A 2008 0.94
38 Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006 0.94
39 Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol 2005 0.94
40 Progress and controversies in developing cancer vaccines. J Transl Med 2005 0.93
41 Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009 0.93
42 Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 2012 0.92
43 A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol 2007 0.92
44 The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol 2012 0.92
45 IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol 2007 0.90
46 Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008 0.89
47 Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother 2006 0.89
48 Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 2012 0.88
49 Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 2007 0.88
50 Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2011 0.85
51 Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. Eur J Immunol 2014 0.84
52 A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012 0.84
53 Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother 2011 0.84
54 Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother 2010 0.84
55 Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother 2007 0.83
56 Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. J Immunol 2004 0.82
57 Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 2006 0.82
58 Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. Cancer Immun 2008 0.81
59 T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013 0.81
60 Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma. Int J Cancer 2010 0.81
61 Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol 2006 0.81
62 Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother 2012 0.80
63 Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. Curr Opin Immunol 2005 0.80
64 MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014 0.80
65 A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts. J Immunol Methods 2012 0.80
66 Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol 2006 0.79
67 Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotechnol 2010 0.79
68 CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother 2012 0.78
69 Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine 2002 0.78
70 Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. PLoS One 2013 0.78
71 Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. Methods Mol Biol 2010 0.78
72 Mobilizing and evaluating anticancer T cells: pitfalls and solutions. Expert Rev Vaccines 2013 0.78
73 Clinical Implications of CD8+ T-cell infiltration in frequent and rare cancers. J Invest Dermatol 2013 0.77
74 Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol 2013 0.77
75 CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. J Mol Med (Berl) 2012 0.77
76 An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immun 2008 0.77
77 Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One 2013 0.76
78 Tumor cell recognition efficiency by T cells. PLoS Med 2005 0.75
79 Endotoxin and asthma. N Engl J Med 2003 0.75
80 Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J Immunother 2009 0.75
81 Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. J Immunol 2006 0.75
82 Conference scene: Immune signatures in the tumor and beyond. Immunotherapy 2012 0.75
83 Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? J Immunother 2016 0.75